Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review.
Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review.
复制标题
DOI：
10.1186/1471-2407-13-158
复制
发表时间：
2013-03-27
期刊：
影响因子：
3.8
通讯作者：
Mills G
中科院分区：
文献类型：
--
作者：
Jafri SH;Shi R;Mills G
全身性炎症与癌症发展、癌症恶病质和不良预后有关。晚期肺癌炎症指数（ALI）用于评估转移性非小细胞肺癌（NSCLC）患者诊断时的全身炎症程度。在一项单机构回顾性研究中，纳入了2000年1月1日至2011年6月30日诊断的173例转移性非小细胞肺癌患者。ALI计算为（BMI x Alb / NLR），其中BMI =体重指数，Alb =血清白蛋白，NLR（中性粒细胞淋巴细胞比率，全系统炎症的标志）。将患者分为低炎症（ALI≥18）组和高炎症（ALI < 18）组。Kaplan-Meier法估计无进展生存期和总生存期。采用Log-rank检验比较各因素间的存活率。采用多变量Cox回归进行生存分析，以估计各因素的风险比。173例患者中位年龄为57岁，67%为男性，52%为腺癌。ALI评分< 18提示全身性炎症程度高的患者有2个以上转移灶的可能性明显增加，表现不佳，接受化疗的可能性较小。他们的中位无进展生存期和总生存期分别为2.4个月和3.4个月，而ALI患者的中位无进展生存期为5.1个月和8.3个月（P < 0.001）。在多因素分析中，ALI评分<18 （1.42,95% CI 1.003-2.01）仍然与较差的预后显著相关。诊断时ALI（<18）是晚期NSCLC患者预后不良的独立标志。
Systemic inflammation has been linked with cancer development, cancer cachexia and poor outcome. Advanced lung cancer inflammation index (ALI) was developed to assess degree of systemic inflammation at the time of diagnosis in metastatic non-small cell lung (NSCLC) cancer patients. In a single institution retrospective review 173 patients with metastatic NSCLC diagnosed between Jan 1 2000 and June 30 2011 were included. ALI was calculated as (BMI x Alb / NLR) where BMI = body mass index, Alb = serum albumin, NLR (neutrophil lymphocyte ratio, a marker of systemic inflammation). Patients were divided into low inflammation (ALI ≥ 18) and high inflammation (ALI < 18) groups. Kaplan-Meier method was used to estimate progression free survival and overall survival. Log-rank test were used to compare the survivals among various factors. Multivariate Cox regression was used to perform survival analysis in order to estimate the hazards ratio for various factors. Among 173 patients median age was 57 years, 67% were male, 52% had adenocarcinoma. Patients with an ALI score of < 18 suggesting high systemic inflammation were significantly more likely to have more than 2 sites of metastatic disease, have poor performance status and less likely to receive any chemotherapy. Their median progression free survival and overall survival was 2.4 months and 3.4 months as opposed to 5.1 months and 8.3 months in patients with ALI >18 (P < 0.001). On multi-variate analysis ALI score of <18 (1.42, 95% CI 1.003-2.01) remained significantly associated with worse outcome. ALI (<18) at diagnosis is an independent marker of poor outcome in patients with advanced NSCLC.
登录
查看更多内容
影响因子：
158.5
作者：
Sandler, Alan;Gray, Robert;Johnson, David H.
通讯作者：
Johnson, David H.
影响因子：
2
作者：
Wahbah, Mary;Boroumand, Nahal;Eltorky, Mahmoud
通讯作者：
Eltorky, Mahmoud
DOI：
10.1016/j.jtcvs.2008.05.046
发表时间：
2009-02-01
影响因子：
6
作者：
Sarraf, Khaled M.;Belcher, Elizabeth;Lim, Eric
通讯作者：
Lim, Eric
影响因子：
45.3
作者：
Chaturvedi, Anil K.;Caporaso, Neil E.;Engels, Eric A.
通讯作者：
Engels, Eric A.
影响因子：
8.8
作者：
Forrest, L M;McMillan, D C;McArdle, C S;Angerson, W J;Dunlop, D J
通讯作者：
Dunlop, D J